Business & Finance Moderna shares sink after leaked cancer data missed expectations
Melanoma vaccine treatment cut risk of recurrence or death by 58% but failed to exceed Wall Street’s lofty expectations
By
· October 22, 2026 · 1 min read
This article was originally published by
Financial Times
and is republished here under license.
Melanoma vaccine treatment cut risk of recurrence or death by 58% but failed to exceed Wall Street’s lofty expectations
Related
Former CEO of Polar Train LNG tells FT that gas giant Novatek financed and controlled strategic Alaska project without US…
By
· October 24, 2026 · 1 min read
Growth and value shares are set for an overhaul after S&P Dow Jones Indices adopted new rules on how to…
By
· October 24, 2026 · 1 min read
Candidates’ similar names could ‘taint’ the result, argues US Justice Department…
By
· October 23, 2026 · 1 min read
Leave a Reply